The global cancer vaccines market size was valued at USD 9.86 billion in 2025 and is projected to grow from USD 10.97 billion in 2026 to USD 25.78 billion by 2034, registering a CAGR of 11.27% during the forecast period (2026–2034). North America dominated the cancer vaccines market with a market share of 37.51% in 2025.
Cancer vaccines are immunotherapy products designed to stimulate the body's immune system to recognize, target, and destroy cancer cells. They include preventive vaccines that reduce the risk of virus-related cancers and therapeutic vaccines that treat existing cancers by enhancing immune responses against tumor-specific antigens.
The cancer vaccines market demand is driven by the rising global cancer burden, growing adoption of immunotherapy, and increasing investments in oncology research. Advancements in vaccine technologies, expanding clinical trials, and supportive regulatory initiatives are also contributing to cancer vaccines market growth.
Download a Free Sample To learn more about this report,
Growing Transition Toward Personalized Neoantigen-based Cancer Vaccines
The increasing use of precision medicine is driving the transition toward personalized neoantigen-based cancer vaccines tailored to individual patient tumor profiles. Advances in next-generation sequencing and bioinformatics are enabling the identification of patient-specific tumor antigens, improving the precision and effectiveness of therapeutic vaccines. This trend is supporting the development of targeted immunotherapies with enhanced clinical outcomes and reduced off-target effects. For example, Moderna and Merck are advancing personalized mRNA cancer vaccine mRNA-4157/V940 for melanoma in combination with immunotherapy.
Rising Integration of mRNA Technology into Cancer Vaccine Development
Growing confidence in mRNA platforms is accelerating the transition toward next-generation cancer vaccine development. Pharmaceutical companies are leveraging mRNA technology to enable faster vaccine design, scalable manufacturing, and rapid adaptation to multiple tumor types. This shift is expanding clinical research activities and strengthening the oncology immunotherapy pipeline across global markets.
The cancer vaccines market forecasts continued investment activity driven by the rapid expansion of oncology immunotherapy, increasing adoption of personalized cancer vaccines, and strong industry focus on mRNA and neoantigen-based platforms.
Key Investment and Funding Activities in Cancer Vaccines Market, 2025–2026
Infinitopes
USD 35.1 Million (Seed Financing)
In January 2026, Infinitopes completed the second close of its seed financing, raising a total of USD 35.1 million to advance its precision therapeutic cancer vaccine (ITOP1) into first-in-human clinical trials and expand its R&D pipeline.
ErVimmune
USD 19.8 Million (Series A)
In January 2026, ErVimmune raised EUR 17 million in the first closing of its Series A round to support the clinical development of ErVac01, a next-generation therapeutic cancer vaccine targeting tumor antigens derived from human endogenous retroviruses (HERVs).
Source: Secondary Research
The cancer vaccines market is highly exposed to supply chain disruptions due to its dependence on specialized raw materials, cold-chain logistics, and complex biopharmaceutical manufacturing processes. Interruptions in the supply of critical components, biologics, and laboratory reagents can delay vaccine production, clinical trials, and commercial distribution across global markets. The market is demonstrating a capacity-constrained recovery, supported by investments in localized manufacturing, diversified supplier networks, and expanded production capabilities to strengthen long-term supply resilience.
Increasing Biomarker Testing and Expansion of Cancer Vaccine Clinical Trials Drive Market
The growing adoption of biomarker testing and next-generation sequencing is driving demand for cancer vaccines by enabling the identification of patient-specific tumor antigens. Hospitals and cancer centers are increasingly incorporating genomic profiling into routine oncology care, making personalized vaccine development more feasible. This has encouraged biotechnology companies to expand precision immunotherapy pipelines and invest in individualized vaccine manufacturing capabilities.
The rapid expansion of global clinical trials for therapeutic cancer vaccines is driving market demand by validating new treatment approaches across multiple tumor types. Increasing participation from academic institutions, cancer research centers, and biotechnology companies is accelerating product development and improving regulatory confidence. This is encouraging manufacturers to increase investments in scalable production and late-stage clinical programs, strengthening future market supply. The growing volume of successful clinical studies is also improving physician confidence in vaccine-based immunotherapies.
Complex Manufacturing and Personalized Production Processes and Lengthy Clinical Development Restrain Market Expansion
Personalized cancer vaccines rely on patient-specific tumor sequencing, neoantigen identification, and customized manufacturing, making the production process highly complex and resource intensive. Each vaccine must be individually designed and manufactured, resulting in higher production costs and longer treatment timelines compared to conventional therapies.
Cancer vaccines require extensive preclinical and clinical studies to establish long-term safety, therapeutic efficacy, and durable immune responses before receiving regulatory approval. The lengthy development process, coupled with high research and clinical trial costs, increases financial risks and extends the time needed for commercialization. These challenges discourage investment in smaller development programs, delay the launch of new vaccine candidates, and ultimately restrain the overall growth of the cancer vaccines market.
Growth of Cancer Vaccine Manufacturing CDMOs and Growing Adoption of Combination Therapy Regimens Offer Growth Opportunities to Market Players
The increasing demand for specialized manufacturing is creating growth opportunities for contract development and manufacturing organizations and biopharmaceutical companies. As more cancer vaccine candidates enter late-stage clinical trials, developers are outsourcing mRNA production, fill-finish operations, and cold-chain packaging to accelerate commercialization. This trend is expected to strengthen manufacturing capacity and reduce production bottlenecks over the coming years. Companies such as Lonza and Catalent are expanding capabilities to support advanced biologics and mRNA-based therapeutics, including cancer vaccines.
The increasing use of cancer vaccines alongside immune checkpoint inhibitors, targeted therapies, and chemotherapy is creating significant opportunities for vaccine developers and pharmaceutical companies. Combination regimens have demonstrated improved anti-tumor immune responses and are expanding the clinical applications of therapeutic cancer vaccines across multiple tumor types. As more combination therapies receive regulatory approval, demand for cancer vaccines is expected to increase substantially.
Limited Standardization of Tumor Sample Collection and Complex Cold Chain and Time-Sensitive Distribution Challenge Market Growth
Variability in tumor biopsy quality, sequencing workflows, and genomic data interpretation creates challenges in developing effective personalized cancer vaccines. Inconsistent sample quality can delay treatment initiation and reduce the reliability of vaccine design, affecting clinical outcomes.
Many cancer vaccines, particularly personalized mRNA and cell-based candidates, require stringent cold-chain storage and rapid transportation to maintain product stability and therapeutic efficacy. Any disruption in temperature-controlled logistics or delays in delivery can compromise product quality and postpone patient treatment. Establishing and maintaining specialized distribution infrastructure increases operational costs and limits access in regions with inadequate cold-chain capabilities, thereby slowing the broader commercialization of cancer vaccines.
The preventive vaccines segment is expected to grow at a CAGR of 11.84% during the forecast period, owing to established national immunization programs against HPV, inclusion in adolescent vaccination schedules, and expanding gender-neutral vaccination recommendations. Strong government procurement and school-based vaccination initiatives continue to increase coverage rates, sustaining demand across developed and emerging healthcare markets.
The therapeutic vaccines segment is expected to grow at a CAGR of around 12.26% during the forecast period due to increasing integration with immune checkpoint inhibitors, expansion of personalized oncology treatment pathways, and rising late-stage clinical success. Physician confidence in vaccine-based immunotherapy is accelerating adoption across multiple solid tumor indications.
Request Customizationto receive a tailored report.
In 2025, recombinant vaccines accounted for a share of 56.38% due to their established commercial manufacturing platforms, consistent antigen expression, and proven long term safety profile in preventive oncology. Broad regulatory acceptance and extensive clinical use continue to reinforce their leadership across global immunization programs.
The viral vector & DNA cancer vaccines segment is expected to grow at a CAGR of 12.67% during the forecast period, driven by improved in vivo antigen delivery, enhanced cellular immune activation, and expanding research into next-generation vector engineering. Their flexibility in targeting multiple tumor-associated antigens supports continued pipeline expansion.
The cervical cancer accounted for a share of 31.41% in 2025 due to widespread HPV immunization programs, strong public health funding, and well-established disease prevention strategies. High awareness of HPV-associated cancers and routine vaccination recommendations continue to sustain long-term market demand globally.
The bladder cancer segment is expected to grow at a CAGR of 12.05% during the forecast period, driven by increasing development of therapeutic vaccines for non-muscle-invasive disease, high recurrence rates requiring novel treatment options, and growing clinical evaluation of combination immunotherapy approaches.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Strong Oncology Innovation Ecosystem and High Adoption of Cancer Immunotherapy
The North America cancer vaccines market accounted for the largest regional share of 37.51% in 2025, driven by an established oncology research ecosystem, high adoption of advanced immunotherapies, and substantial investments in precision medicine. The region benefits from the presence of leading biotechnology and pharmaceutical companies, robust clinical trial infrastructure, and favorable regulatory pathways for innovative cancer therapies.
The US cancer vaccines market was valued at USD 3.22 billion in 2025, driven by increasing adoption of personalized immunotherapy, strong clinical research activity, and growing investments in mRNA-based oncology platforms. The country hosts a large number of leading cancer research institutes, biotechnology companies, and comprehensive cancer centers that actively support cancer vaccine development and commercialization. According to the American Cancer Society, the US is expected to record more than 2 million new cancer cases in 2025, supporting sustained demand for preventive and therapeutic cancer vaccines.
The cancer vaccines market in Canada was valued at USD 477.25 million in 2025, supported by increasing government investments in cancer research, expanding precision oncology initiatives, and growing participation in international clinical trials. Healthcare institutions are strengthening capabilities in genomic medicine and immunotherapy to improve cancer treatment outcomes. Canada's collaborative research environment, universal healthcare system, and increasing focus on innovative oncology treatments continue to create favorable conditions for the adoption of cancer vaccines.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Driven by Expansion of Genomic Medicine Networks and Increasing Government-backed Oncology Immunization Initiatives
The Asia Pacific cancer vaccines market is expected to grow at a CAGR of 13.02% during the forecast period, showcasing the fastest regional growth. Growth is supported by rapid expansion of genomic medicine networks, increasing government-backed oncology immunization initiatives, and growing participation in multinational cancer vaccine clinical studies. Healthcare systems across the region are strengthening molecular diagnostics infrastructure, improving access to precision oncology, and accelerating regulatory pathways for innovative cancer immunotherapies.
The China cancer vaccines market was valued at USD 563.64 million in 2025, supported by establishment of national cancer genomic databases, increasing domestic mRNA manufacturing capabilities, and strong policy support for locally developed oncology biologics. The country is rapidly expanding hospital-based precision oncology programs and integrating advanced molecular testing into cancer treatment pathways.
The India cancer vaccines market was valued at USD 288.30 million in 2025, fueled by the growth of affordable genomic testing services, increasing oncology treatment penetration in private healthcare networks, and rising government focus on cervical cancer prevention initiatives. Leading multispecialty hospital groups are strengthening immunotherapy and molecular oncology capabilities to support advanced cancer care.
The Japan cancer vaccines market was valued at USD 332.64 million in 2025, supported by Japan’s advanced precision medicine ecosystem, strong integration of biomarker-guided oncology treatment, and early adoption of personalized immunotherapy approaches. Japanese healthcare institutions are increasingly incorporating genomic profiling into routine cancer management, enabling more targeted vaccine development and patient selection.
The cancer vaccines market competitive landscape is consolidated, with competition led by global pharmaceutical and biotechnology companies possessing strong oncology portfolios and advanced immunotherapy capabilities. Leading players compete through proprietary mRNA platforms, personalized neoantigen technologies, robust clinical pipelines, and strategic investments in research and manufacturing. High entry barriers associated with scientific expertise, regulatory requirements, and capital-intensive development further reinforce market concentration.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Uterine Fibroid Drugs Market Size, Share, Growth, 2034
Bispecific T Cell Engager Therapeutics Market Size, Share, 2034
Antiviral Drugs Market Size, Share, Growth, Analysis, 2034
Branded Generics Market Size, Share, Growth, Forecast, 2034
Oncology Drugs Market Size, Share, Growth, Analysis, Report, 2034
Alzheimer’s Therapeutics Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com